TIDMSTX

RNS Number : 8289G

Shield Therapeutics PLC

31 March 2022

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Block Listing Application

London, UK, 31 March 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru(R)/Accrufer(R) ( ferric maltol), has today made an application to the London Stock Exchange for a block listing of 2,000,000 ordinary shares of 1.5 pence each in the Company ("Block Listing Shares") to be admitted to trading on the London Stock Exchange ("Admission").

The 2,000,000 Block Listing Shares are to be issued under the Shield Therapeutics Retention and Performance Share Plan.

Admission is expected to occur on 06 April 2022.

For further information please contact:

 
 Shield Therapeutics plc                                        www.shieldtherapeutics.com 
 Greg Madison, CEO                                                    +44 (0) 191 511 8500 
 Hans-Peter Rudolf, CFO 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Christopher Golden                                        +44 (0)20 7418 8900 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Alice Lane/George 
   Dollemore                                                           +44 (0)20 7220 0500 
 
 Financial PR & IR Advisor 
 Walbrook PR (UK Advisor) 
 Paul McManus/Lianne Applegarth/Alice         +44 (0)20 7933 8780 or shield@walbrookpr.com 
  Woodings 
 
  Investor Contact (US Advisor) 
 LifeSci Advisors, LLC 
  John Mullaly                             +1 617 429 3548 or jmullaly@lifesciadvisors.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer(R)/Feraccru(R) (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Accrufer(R)/Feraccru(R), has been approved for use in the United States, European Union, UK, Switzerland, and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer (R) in the US. Feraccru(R) is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer(R)/Feraccru(R) in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSZFLFXLXLZBBF

(END) Dow Jones Newswires

March 31, 2022 10:50 ET (14:50 GMT)

Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Shield Therapeutics.
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Shield Therapeutics.